Low-dose lithium adjunct therapy associated with reduced off-time in Parkinson's disease: A case series

Journal of the Neurological Sciences

Volumn 368, Issue , 2016, Pages 221-222

  Guttuso, Thomas ^a  

^a NONE   (United States)

Author keywords

Dyskinesias; Lithium; Motor fluctuations; Off time; Parkinson's disease

Indexed keywords

LEVODOPA; LITHIUM; ANTIPARKINSON AGENT; LITHIUM CHLORIDE;

ADULT; AGED; BIPOLAR DISORDER; CLINICAL ARTICLE; DEMENTIA; DISEASE DURATION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; DYSKINESIA; FEMALE; HAND TREMOR; HUMAN; HYPOTHYROIDISM; LETTER; LOW DRUG DOSE; MALE; MIDDLE AGED; PARKINSON DISEASE; PRIORITY JOURNAL; TIME SERIES ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; URINE INCONTINENCE; VISUAL HALLUCINATION; FOLLOW UP;

AGED; ANTIPARKINSON AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEVODOPA; LITHIUM CHLORIDE; MALE; MIDDLE AGED; PARKINSON DISEASE;

EID: 84978430466     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2016.07.027     Document Type: Letter

References (10)

1. [1] Coffey, C.E., Ross, D.R., Ferren, E.L., Sullivan, J.L., Olanow, C.W., Treatment of the “on-off” phenomenon in Parkinsonism with lithium carbonate. Ann. Neurol. 12:4 (1982), 375–379.
2. [2] Coffey, C.E., Ross, D.R., Massey, E.W., Olanow, C.W., Dyskinesias associated with lithium therapy in parkinsonism. Clin. Neuropharmacol. 7:3 (1984), 223–229.
3. [3] Quinn, N., Marsden, C.D., Lithium for painful dystonia in Parkinson's disease. Lancet, 1(8494), 1986, 1377.
4. [4] Aprahamian, I., Santos, F.S., dos Santos, B., Talib, L., Diniz, B.S., Radanovic, M., et al. Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension. J. Clin. Psychiatry 75:7 (2014), e672–e678.
5. [5] Pert, A., Rosenblatt, J.E., Sivit, C., Pert, C.B., Bunney, W.E. Jr., Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity. Science 201:4351 (1978), 171–173.
6. [6] Goetz, C.G., Wuu, J., McDermott, M.P., Adler, C.H., Fahn, S., Freed, C.R., et al. Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions. Mov. Disord. 23:5 (2008), 690–699.
7. [7] Lazzara, C.A., Kim, Y.H., Potential application of lithium in Parkinson's and other neurodegenerative diseases. Front. Neurosci., 9, 2015, 403.
8. [8] Dewey, R.B. Jr., Management of motor complications in Parkinson's disease. Neurology 62:6 Suppl. 4 (2004), S3–S7.
9. [9] Kleiner-Fisman, G., Herzog, J., Fisman, D.N., Tamma, F., Lyons, K.E., Pahwa, R., et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov. Disord. 21:Suppl. 14 (2006), S290–S304.
10. [10] Wirdefeldt, K., Odin, P., Nyholm, D., Levodopa-carbidopa intestinal gel in patients with Parkinson's disease: a systematic review. CNS Drugs 30:5 (2016), 381–404.